FGEN vs. ADAG, IMUX, ABEO, RZLT, COYA, CLRB, DMAC, VTGN, CRVS, and CTXR
Should you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Adagene (ADAG), Immunic (IMUX), Abeona Therapeutics (ABEO), Rezolute (RZLT), Coya Therapeutics (COYA), Cellectar Biosciences (CLRB), DiaMedica Therapeutics (DMAC), Vistagen Therapeutics (VTGN), Corvus Pharmaceuticals (CRVS), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical preparations" industry.
Adagene (NASDAQ:ADAG) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
Adagene presently has a consensus price target of $5.00, indicating a potential upside of 96.08%. FibroGen has a consensus price target of $17.00, indicating a potential upside of 1,316.67%. Given Adagene's higher possible upside, analysts plainly believe FibroGen is more favorable than Adagene.
Adagene has a net margin of 0.00% compared to Adagene's net margin of -143.57%.
FibroGen received 325 more outperform votes than Adagene when rated by MarketBeat users. However, 78.26% of users gave Adagene an outperform vote while only 62.36% of users gave FibroGen an outperform vote.
Adagene has higher earnings, but lower revenue than FibroGen.
9.5% of Adagene shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 2.0% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Adagene has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
In the previous week, Adagene had 2 more articles in the media than FibroGen. MarketBeat recorded 2 mentions for Adagene and 0 mentions for FibroGen. Adagene's average media sentiment score of 0.25 beat FibroGen's score of -0.13 indicating that FibroGen is being referred to more favorably in the news media.
Summary
Adagene beats FibroGen on 9 of the 15 factors compared between the two stocks.
Get FibroGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroGen Competitors List
Related Companies and Tools
